The shifting paradigm of a “cure” for type 1 diabetes: is technology replacing immune-based therapies?
Authors:
- 29 November 2017
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 55 (2) , 117-120
Abstract
Nearly 50 years after the autoimmune nature of type 1 diabetes was discovered, no therapy has been approved to alter the course of the disease at any stage. However, during that same period, technology has been delivering tools to help patients achieve better glycemic control and reduce the burden of the disease. With the imminent arrival of fully automated artificial pancreas systems that will continue to improve control and quality of life, it appears that we are on the verge of a major technological breakthrough that will significantly impact diabetes care. These devices have such a high degree of potential that they are, at times, mentioned as a virtual cure for the disease—a first for technology in this space. As such, these devices will undoubtedly alter the research landscape in a field that has predominantly been occupied by immunotherapies. This article reviews the history of type 1 diabetes and compares and contrasts the advancements that have come from the world of technology and immunology alike at this important crossroads in care that we are currently in.Keywords
This publication has 11 references indexed in Scilit:
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesJAMA, 2016
- Progress and challenges for treating Type 1 diabetesJournal of Autoimmunity, 2016
- Understanding the sources of diabetes distress in adults with type 1 diabetesJournal of Diabetes and its Complications, 2015
- Outpatient Glycemic Control with a Bionic Pancreas in Type 1 DiabetesNew England Journal of Medicine, 2014
- EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?Expert Review of Clinical Immunology, 2013
- GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes MellitusNew England Journal of Medicine, 2012
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes MellitusJAMA, 2007
- Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent OnsetScience, 1984
- ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIESThe Lancet, 1974